Vanda Pharmaceuticals’ VQW-765 Trial Fails to Meet Primary Endpoint
Vanda said the Phase 3 trial of VQW-765 for anxiety did not meet its primary endpoint, which measured distress during the performance phase of the Trier Social Stress Test in women.
Vanda Pharmaceuticals said its trial of VQW-765 for anxiety did not meet its primary endpoint. The Phase 3 trial measured distress during the performance phase of the Trier Social Stress Test, a measure of social anxiety, in women, the company said Wednesday.